News und Analysen
The Fundamental Issue With NVIDIA Might Be Its Fundamentals
Is NVIDIA Corp. (NASDAQ: NVDA) a proxy for the broader market? It sure looks like it. In late August, the world’s leading microchip manufacturer delivered a strong earnings report. However
The Fundamental Issue With NVIDIA Might Be Its Fundamentals
Is NVIDIA Corp. (NASDAQ: NVDA) a proxy for the broader market? It sure looks like it. In late August, the world’s leading microchip manufacturer delivered a strong earnings report. However
The Fundamental Issue With NVIDIA Might Be Its Fundamentals
Is NVIDIA Corp. (NASDAQ: NVDA) a proxy for the broader market? It sure looks like it. In late August, the world’s leading microchip manufacturer delivered a strong earnings report. However
3 Stocks to Watch as Firms Cut Costs Ahead of Potential Recession
Investors today are worried about a potential recession in the United States economy, considering some slowing indicators such as inflation and employment. Today, more than ever, the two camps are
3 Stocks to Watch as Firms Cut Costs Ahead of Potential Recession
Investors today are worried about a potential recession in the United States economy, considering some slowing indicators such as inflation and employment. Today, more than ever, the two camps are
3 Stocks to Watch as Firms Cut Costs Ahead of Potential Recession
Investors today are worried about a potential recession in the United States economy, considering some slowing indicators such as inflation and employment. Today, more than ever, the two camps are
3 Stocks to Watch as Firms Cut Costs Ahead of Potential Recession
Investors today are worried about a potential recession in the United States economy, considering some slowing indicators such as inflation and employment. Today, more than ever, the two camps are
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics
Emerging Markets: What They Are and Why They Matter
Emerging markets are rapidly growing economies transitioning from developing status to becoming major players on the global stage. They have experienced notable shifts in their economic structures
Recession or Not, These 3 Stocks Are Winners
A lot of chatter has been going on around the subject of the U.S. economic situation right now. On one side, some market participants think that the S&P 500 could keep on making new all-time
Recession or Not, These 3 Stocks Are Winners
A lot of chatter has been going on around the subject of the U.S. economic situation right now. On one side, some market participants think that the S&P 500 could keep on making new all-time
Why NVIDIA Is More of a Screaming Buy Than Ever
Few investors at the start of the year would have expected NVIDIA Corporation (NASDAQ: NVDA) to be “trading in bear territory” by the end of the summer. But that’s exactly what Goldman Sachs
Why NVIDIA Is More of a Screaming Buy Than Ever
Few investors at the start of the year would have expected NVIDIA Corporation (NASDAQ: NVDA) to be “trading in bear territory” by the end of the summer. But that’s exactly what Goldman Sachs
Why NVIDIA Is More of a Screaming Buy Than Ever
Few investors at the start of the year would have expected NVIDIA Corporation (NASDAQ: NVDA) to be “trading in bear territory” by the end of the summer. But that’s exactly what Goldman Sachs
Don't Miss These 3 Stocks Set to Defy Expectations in September
September is often volatile for the stock market, with opportunities for investors to capitalize on market shifts. While economic uncertainty lingers, fueled by factors like inflation, rising
Don't Miss These 3 Stocks Set to Defy Expectations in September
September is often volatile for the stock market, with opportunities for investors to capitalize on market shifts. While economic uncertainty lingers, fueled by factors like inflation, rising
Don't Miss These 3 Stocks Set to Defy Expectations in September
September is often volatile for the stock market, with opportunities for investors to capitalize on market shifts. While economic uncertainty lingers, fueled by factors like inflation, rising
Top 3 Emerging Market ETFs to Watch as the U.S. Dollar Weakens
As U.S. interest rates remain elevated and the dollar continues its strong run for much of 2024, emerging market equities have still delivered impressive performances. While trailing behind the
As Home Prices Hit Highs, These Apartment REITs Offer Growth
Investors might wonder whether the real estate sector will see a demand boon soon. Leaning on the promise of a Federal Reserve interest rate cut by the end of the year, most of the market is on
3 ETFs to Build a Simple and Balanced Stock Portfolio
With so many investment options, it can feel overwhelming to choose the best combination. This can lead to having lots of positions, making it feel like there is always something to monitor and
Charles Schwab’s Initiative Changes Are a Long-Term Positive
The cliché "Short-term pain for long-term gain" rings true in the stock market, notably during earnings season. Companies that miss forecasts or cut guidance find their stocks punished as
Charles Schwab’s Initiative Changes Are a Long-Term Positive
The cliché "Short-term pain for long-term gain" rings true in the stock market, notably during earnings season. Companies that miss forecasts or cut guidance find their stocks punished as
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2024-2025 vaccination season, pending a European Commission authorization decision
CAMBRIDGE, MA / ACCESSWIRE / September
Ausschuss für Humanarzneimittel der EMA gibt positive Stellungnahme ab und empfiehlt Zulassung von Modernas COVID-19-mRNA-Impfstoff, der gegen die SARS-COV-2-Variante JN.1 gerichtet ist
Modernas neu angepasster COVID-19-mRNA-Impfstoff wird für die Impfsaison 2024 und 2025 zur Verfügung stehen – die Zulassungsentscheidung der Europäischen Kommission steht noch aus
3 Stocks to Watch as the Economy Shifts to the Cloud
Investors who want to get on the train for the next big waves of innovation and adoption in the global economy have a special opportunity today. The technology sector is carrying some of the